Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system (CNS) affecting the brain, spinal cord, and optic nerves. In MS, inflammatory immune activity damages myelin and, over time, may also produce axonal and neuronal injury.

The resulting neurological manifestations vary considerably depending on the location of CNS lesions. Patients may experience visual disturbances, weakness, sensory abnormalities, impaired coordination, bladder dysfunction, and numerous other neurological symptoms.

A defining feature of MS is that neurological dysfunction can occur in different CNS locations and at different points in time, a concept known as dissemination in space and time.

Epidemiology & Risk Factors

MS can develop at almost any age, but onset most commonly occurs in young adulthood (ages 20 to 40). Women develop relapsing forms of MS more frequently than men. Historically, MS has been more prevalent at higher geographic latitudes.

Disease development involves an interaction between genetic susceptibility and environmental exposures:

• Epstein-Barr Virus (EBV): A strong epidemiological relationship exists with prior EBV infection, though EBV alone is insufficient to cause disease.
• Vitamin D Status: Low vitamin D levels are linked to increased MS risk and disease activity.
• Other Contributors: Family history, cigarette smoking, geographic location, and coexisting autoimmune disorders.

Pathophysiology

In health, myelin surrounds CNS nerve fibers to facilitate rapid electrical signaling. In MS, immune-mediated inflammation damages this protective myelin sheath.

Normal myelin → Immune-mediated inflammation → Demyelination → Impaired nerve conduction → Neurological deficits

Repeated inflammatory injury can eventually result in demyelinating plaques, gliosis (scarring), axonal injury, CNS volume loss, and progressive neurological disability. While early lesions may show partial recovery through remyelination, severe or repeated injury produces permanent deficits.

Clinical Patterns of Multiple Sclerosis

MS Subtype	Disease Course & Pattern	Key Characteristics
Relapsing-Remitting (RRMS)	Clearly defined relapses followed by periods of partial or complete recovery (remission).	Most common initial presentation. Relapses evolve over hours/days and persist for days to weeks.
Secondary Progressive (SPMS)	Gradual accumulation of disability following an initial RRMS course.	Progressive decline may occur with or without occasional superimposed relapses.
Primary Progressive (PPMS)	Gradual worsening of neurological function from disease onset without initial relapses.	Progressive deterioration from onset rather than resolved discrete attacks.

Clinical Manifestations

Symptoms depend on the specific CNS location of demyelinating lesions:

• Visual (Optic Neuritis): Acute/subacute monocular vision loss, decreased acuity, dyschromatopsia (altered color perception), and eye pain with movement. Diplopia occurs with brainstem ocular pathway involvement.
• Sensory & Motor: Paresthesias, numbness, burning, altered temperature sensation, limb weakness, spasticity, hyperreflexia, and gait impairment.
• Cerebellar & Brainstem: Ataxia, intention tremor, impaired coordination, nystagmus, facial numbness/weakness, and vertigo.
• Autonomic & Constitutional: Bladder, bowel, and sexual dysfunction, alongside severe fatigue and cognitive changes.

Heat Sensitivity (Uhthoff Phenomenon)

Transient worsening of neurological symptoms following an increase in core body temperature (e.g., hot weather, hot showers, fever, strenuous exercise). It represents conduction slowing through previously demyelinated axons rather than new CNS tissue damage, resolving once body temperature normalizes.

Relapse vs. Pseudo-Relapse

• True Relapse: New or worsening focal neurological symptoms lasting ≥24 hours in the absence of fever or infection, driven by active CNS inflammation.
• Pseudo-Relapse: Temporary worsening of pre-existing deficits without new CNS inflammation, commonly triggered by infection (especially UTIs), fever, heat, or physiological stress.

Clinical Pearl: Always rule out underlying systemic infection—particularly a urinary tract infection—when an MS patient presents with abrupt neurological worsening.

Diagnostic Evaluation

MS is diagnosed by integrating clinical history, physical examination, neuroimaging, and supportive laboratory studies. Diagnosis relies on the McDonald Criteria to establish Dissemination in Space (DIS) and Dissemination in Time (DIT) while excluding alternative diagnoses.

• Brain & Spinal Cord MRI: The primary imaging modality. Demonstrates characteristic demyelinating lesions in periventricular, cortical/juxtacortical, infratentorial, and spinal cord regions. Contrast enhancement identifies active inflammatory lesions.
• CSF Analysis: Lumbar puncture demonstrates CSF-restricted oligoclonal IgG bands (indicating intrathecal antibody synthesis) and elevated IgG index. Mild mononuclear pleocytosis or mild protein elevation may be present.
• Evoked Potentials: Visual Evoked Potentials (VEPs) detect subclinical conduction slowing along optic pathways.
• Blood Testing: Used strictly to exclude mimics (e.g., B12 deficiency, NMOSD, MOGAD, systemic autoimmune/rheumatologic disease, neuro-syphilis).

Therapeutic Management

MS management encompasses three distinct strategies: treating acute attacks, disease modification, and symptomatic management.

1. Management of Acute Relapses

• High-Dose Corticosteroids: Intravenous methylprednisolone accelerates symptom recovery by reducing acute CNS inflammation. Steroids do not alter long-term disease progression or prevent future attacks.
• Plasma Exchange (PLEX): Indicated for severe, disabling acute demyelinating attacks that are refractory to high-dose corticosteroid therapy.

2. Disease-Modifying Therapies (DMTs)

Therapy / Class	Mechanism of Action	Key Clinical Considerations & Adverse Risks
Interferon beta / Glatiramer acetate	Injectable immunomodulators; alters immune responses against myelin.	Flu-like symptoms, injection site reactions, hepatic/CBC monitoring.
Dimethyl fumarate / Teriflunomide	Oral agents; immunomodulation and lymphocyte proliferation inhibition.	GI effects, lymphopenia, flushing. Teriflunomide carries major hepatoxicity and teratogenicity risks.
Fingolimod	Sphingosine-1-phosphate receptor modulator; sequesters lymphocytes in nodes.	First-dose bradycardia/heart block, macular edema, infection risk, rebound disease on cessation.
Natalizumab	Alpha-4 integrin monoclonal antibody; blocks leukocyte CNS entry.	High risk of Progressive Multifocal Leukoencephalopathy (PML) via JC virus reactivation. Stratified by anti-JCV antibody status.
Ocrelizumab / B-cell Depleting Agents	Anti-CD20 monoclonal antibody; depletes CD20+ B cells.	Approved for RRMS and PPMS. Infusion reactions, increased infection risk, hypogammaglobulinemia.
Alemtuzumab	Anti-CD52 monoclonal antibody; causes rapid immune cell depletion.	High risk of secondary autoimmune conditions (thyroid disorders, ITP) requiring prolonged monitoring.

Summary Takeaways

• MS is an immune-mediated demyelinating disorder characterized by CNS lesions separated in time and space.
• The McDonald criteria require demonstrating Dissemination in Space and Time via clinical exam, MRI, and CSF oligoclonal bands.
• Always rule out pseudo-relapses (e.g., secondary to fever or UTI) before treating for an acute inflammatory MS relapse.
• High-dose steroids accelerate acute recovery; PLEX is reserved for refractory attacks.
• DMT drug selection depends on disease subtype, viral serologies (e.g., JC virus antibody testing for Natalizumab PML risk), and cardiac safety (Fingolimod).